Neuroinflammation in schizophrenia: cytokines, microglia, complement

For most of the twentieth century, the immune system and the brain were treated as separate worlds. The brain was supposed to be "immune-privileged," sealed off behind the blood-brain barrier and largely uninvolved in the inflammatory processes that played out elsewhere in the body. That picture has fallen apart over the last twenty years. The brain has its own resident immune cells, communicates constantly with the peripheral immune system, and uses immune molecules for some of its most basic functions — including pruning synapses during development.

Schizophrenia, it turns out, sits squarely in the middle of that revised understanding.

The major players

Microglia

Microglia are the brain's resident immune cells. In a healthy adult brain, they patrol territory, prune unused synapses, clean up cellular debris, and respond to injury. In schizophrenia, postmortem and PET studies have repeatedly suggested that microglia are more activated than expected, particularly in cortical regions. Some research using PET tracers for the TSPO protein (a marker of microglial activation) has found elevated signals in patients with schizophrenia, although the literature is mixed and methodologically tricky.

Cytokines

Cytokines are small signalling proteins that immune cells use to communicate. Several large meta-analyses, notably from the Brian Miller group, have found that people with schizophrenia tend to have elevated peripheral levels of pro-inflammatory cytokines — particularly interleukin-6 (IL-6), TNF-α, and CRP — both during acute episodes and to a lesser degree during remission. Whether this elevation is a cause, a consequence, or a marker of something else (stress, weight gain, smoking, antipsychotics) is still debated.

The complement cascade

Complement is a set of proteins that act as part of the innate immune system, tagging unwanted material for removal. In the brain, complement also helps mark synapses for elimination during normal development — a process called synaptic pruning. In 2016, a landmark study by Aswin Sekar, Beth Stevens, and Steve McCarroll, published in Nature, linked the strongest schizophrenia genetic risk locus (the MHC region) to structural variation in the gene for complement component 4 (C4). Higher-expressing C4 alleles raised schizophrenia risk, possibly by causing excessive synaptic pruning during adolescence — exactly the developmental window when schizophrenia typically emerges.

The C4 finding is one of the most influential discoveries in modern schizophrenia genetics. It suggests that an immune-related developmental process may help explain why schizophrenia tends to appear in the late teens and early twenties.

Other immune-related observations

• Maternal infection during pregnancy — particularly in the second trimester — is associated with a modestly increased schizophrenia risk in offspring, an effect studied in detail in animal models of "maternal immune activation."
• Autoimmune disease generally is more common in people with schizophrenia, and vice versa.
• Anti-NMDA receptor encephalitis can present as a schizophrenia-like syndrome and is treatable with immunotherapy — a vivid demonstration that immune attack on the brain can mimic schizophrenia.
• HLA region genes involved in immune function show some of the strongest genetic associations with schizophrenia.

What this does not mean

The neuroinflammation literature deserves an honest reading. Several caveats:

• Elevated peripheral cytokines are also seen in depression, bipolar disorder, obesity, smoking, and chronic stress. They are not specific to schizophrenia.
• Antipsychotic medications themselves can affect inflammatory markers, complicating cross-sectional studies.
• PET studies of microglia have produced inconsistent results, partly because the standard tracer (TSPO) is influenced by genetic variation and by changes in non-microglial cells.
• The C4 effect, while robust, accounts for only a small portion of schizophrenia risk.
• Anti-inflammatory drug trials in schizophrenia have produced inconsistent results.

None of this overturns the inflammation story — it just sets the bar honestly. Schizophrenia almost certainly is not purely an inflammatory disorder. It may, in some patients or some phases, have an immune component that contributes meaningfully to onset, symptoms, or course.

What anti-inflammatory treatments have shown

Several adjunctive anti-inflammatory medications have been tested as add-ons to antipsychotics:

• Aspirin and other NSAIDs — small positive signals in some meta-analyses, far from definitive.
• Minocycline — a tetracycline antibiotic with anti-inflammatory and microglia-modulating effects. Early trials suggested possible benefit on negative symptoms; later, larger trials (including BeneMin) were largely negative.
• N-acetylcysteine — modulates oxidative stress and glutamate signalling. Mixed but mildly encouraging results, particularly for negative symptoms.
• Omega-3 fatty acids — some signal in early-intervention populations (notably Amminger's prevention trial); subsequent trials have been mixed.
• Celecoxib — selective COX-2 inhibitor; early studies suggested small additive benefit, not robustly replicated.

None of these is standard treatment, and none should be taken without conversation with a prescriber.

Where research is heading

• Better PET tracers for microglial activity that avoid TSPO's confounders
• Clarifying which immune subgroups within schizophrenia might respond to immune-targeted treatments
• Following high-risk individuals over time to see whether immune markers change before a first episode
• Testing biologic anti-inflammatory drugs (such as IL-6 receptor antagonists) in carefully selected populations
• Understanding how maternal infection, childhood adversity, and adolescent inflammation interact with genetic risk

What this means for patients today

Practically, very little — for now. Anti-inflammatory drugs are not part of standard schizophrenia care. But the immune story does have clinical implications worth knowing about:

• Sudden, severe new-onset psychosis warrants a medical workup that screens for autoimmune encephalitis, particularly anti-NMDA receptor encephalitis, which is treatable.
• Schizophrenia is associated with elevated cardiometabolic risk, which itself is partly inflammatory. Lifestyle interventions that reduce inflammation (sleep, exercise, diet) have multiple benefits.
• The immune story is one reason why the next generation of schizophrenia treatments may look very different from the dopamine-blocking pills of the past 70 years.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.